Physician profile
Meredith Clark
NPI 1629793229
$764.51
in general payments reported to CMS, 2019-2025
15 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $76.66 · 2024: $570 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $196.88 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $117.80 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $76.70 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $59.46 | 2024 | |
| Axsome Therapeutics, INC. | $57.18 | 2023-2024 | Auvelity |
| Biotronik Nro, INC. | $56.94 | 2025 | Prospera |
| Abbvie INC. | $44.28 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $30.59 | 2024 | Farxiga, Airsupra |
| Esperion Therapeutics, INC. | $21.01 | 2024 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.75 | 2024 | Caplyta |
| Agile Therapeutics, INC. | $18.06 | 2023 | Twirla |
| Pfizer INC. | $18.01 | 2024 | |
| Antares Pharma, INC. | $16.84 | 2024 | Xyosted |
| Teva Pharmaceuticals USA, INC. | $16.51 | 2023 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $14.50 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.